UroGen Pharma Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenues: $27.5 million, comprising $25.7 million from JELMYTO and $1.8 million from ZUSDURI.

JELMYTO Revenue Growth: 13% increase year-over-year, excluding $2.6 million in CREATES Act sales from the same period in 2024.

Net Loss: $33.3 million, or $0.69 per share, compared to a net loss of $23.7 million, or $0.51 per share in Q3 2024.

Cash Position: $127.4 million as of September 30, 2025.

R&D Expenses: $14 million, up from $11.4 million in Q3 2024, primarily due to costs associated with the UGN-103 trial.

SG&A Expenses: $37.6 million, an increase from $28.9 million in the prior year, driven by ZUSDURI commercial preparation and sales force expansion.

2Strategic Updates and Business Highlights

ZUSDURI Launch: Initial uptake slower than anticipated due to logistical challenges and reimbursement issues. However, October's preliminary demand revenue of $4.5 million indicates a doubling of adoption compared to previous months.

JELMYTO Performance: Continued strong demand with a solid clinical value and prescriber confidence.

Clinical Advancements: UGN-103's NDA submission is planned for the second half of 2026, with potential approval in 2027. UGN-501 is in IND-enabling studies, with a Phase I trial expected in 2026.

Market Access: Broad coverage achieved for ZUSDURI across major payers, with over 95% of covered lives.

3Forward Guidance and Outlook

JELMYTO Revenue Guidance: Expected net product revenues for 2025 in the range of $94 million to $98 million, reflecting 8% to 12% growth year-over-year.

Operating Expenses: Guidance remains unchanged at $215 million to $225 million for 2025.

ZUSDURI Adoption: Anticipated acceleration in adoption post-January 1, 2026, when a permanent J-code will simplify reimbursement processes.

4Challenges and Points of Concern

ZUSDURI Adoption Delays: Conversion from patient enrollment forms (PEFs) to actual dosing is taking longer than expected (45-60 days), primarily due to administrative hurdles and the temporary miscellaneous J-code.

Net Loss Increase: The net loss has widened compared to the previous year, raising concerns about financial sustainability.

UGN-301 Discontinuation: The program was halted due to insufficient clinical profile for advancement, redirecting focus to UGN-103 and UGN-501.

5Notable Q&A Insights

Physician Feedback: Many physicians are waiting for the permanent J-code before prescribing ZUSDURI, indicating a potential backlog of demand.

Community vs. Institutional Treatment: Currently, 35-40% of ZUSDURI treatments are in community settings, with expectations for growth in this area once the J-code is active.

Patient Enrollment Forms: Strong month-over-month growth in PEFs, with current numbers comparable to JELMYTO, suggesting healthy demand.

Cash Position and Future Needs: Management believes current cash reserves are sufficient to reach profitability, but will remain disciplined regarding future capital needs. Overall, UroGen Pharma is navigating a challenging launch environment for ZUSDURI but remains optimistic about long-term growth potential, particularly with the upcoming permanent J-code and ongoing clinical advancements.